Skip to content

Michael Burry buys 634,000 shares of this $1 penny stock

Michael Burry buys 634,000 shares of this $1 penny stock
Jordan Major

When Michael Burry, the man who famously bet against the housing market before the 2008 financial crash, makes a move, investors take notice. 

His hedge fund, Scion Asset Management, acquired 633,959 shares of BioAtla (NASDAQ: BCAB) for $1.37 each during the second quarter, making 1.65% of his portfolio

BioAtla shares started to move upward, finishing Monday at $1.76 and rising 6.81% pre-market on Tuesday, October 1st, to $1.88, suggesting growing confidence in the company’s future, particularly with today’s announcement of its acceptance of an abstract for Oral Presentation at the Society for Melanoma Research 21st International Congress in New Orleans.

BioAlta pre-market 6.88% spike. Source: Google Finance

With the stock currently trading around $1.88 after spiking todays spike, Burry is now up 37.2%, meaning this penny stock purchase has begun to catch the attention of many investors. 

But, what makes this particular play interesting?

Why is Michael Burry interested?

As a contrarian investor, Burry has built a reputation for finding undervalued opportunities. BioAtla, which has seen a massive decline of over 90% since its peak in late 2020, fits the profile. While the stock has struggled, it’s clear that Burry sees potential in the company’s innovative pipeline.

BioAtla’s focus on antibody-based cancer therapies could be game-changing, particularly if their phase 2 programs show positive results. However, investing in a company at this stage is risky. Clinical trials can take time, and success is far from guaranteed. Still, the potential rewards are significant, and Burry’s bet suggests that he sees value where others don’t.

BioAtla stock potential

Burry’s fund, at around $52 million in assets, is relatively small compared to Wall Street’s giants. For a fund of this size, a penny stock like BioAtla can offer significant returns if things go well. 

BioAtla’s current market cap stands at $78 million, meaning that even modest gains could make a big difference for Burry’s portfolio.

However, it’s essential to recognize the risks. The biotech sector is notoriously volatile, and clinical trials often take longer than expected, with uncertain outcomes. That said, for those willing to take on some risk, following in Burry’s footsteps could lead to significant upside if BioAtla’s CAB technology proves successful.

Best Crypto Exchange for Intermediate Traders and Investors

  • Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.

  • 0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.

  • Copy top-performing traders in real time, automatically.

  • eToro USA is registered with FINRA for securities trading.

30+ million Users
Securities trading offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. Finbold.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD

Read Next:

Finance Digest

By subscribing you agree with Finbold T&C’s & Privacy Policy

Related posts

Sign Up

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

Already have an account? Sign In

Disclaimer: The information on this website is for general informational and educational purposes only and does not constitute financial, legal, tax, or investment advice. This site does not make any financial promotions, and all content is strictly informational. By using this site, you agree to our full disclaimer and terms of use. For more information, please read our complete Global Disclaimer.